Latest Insider Transactions at Gemini Therapeutics, Inc. (GMTX)
This section provides a real-time view of insider transactions for Gemini Therapeutics, Inc. (GMTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Gemini Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Gemini Therapeutics, Inc. 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2023
|
Rahul Khara Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,900
+50.0%
|
$68,600
$14.69 P/Share
|
|
Nov 03
2023
|
Rahul Khara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$5,000
$50.0 P/Share
|
|
Nov 03
2023
|
Rahul Khara Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$1,400
$14.69 P/Share
|
|
Sep 16
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,115
-0.13%
|
$112,095
$53.22 P/Share
|
|
Sep 15
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
260,894
-14.05%
|
$13,827,382
$53.16 P/Share
|
|
Sep 14
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
94,440
-4.84%
|
$5,005,320
$53.05 P/Share
|
|
Sep 11
2023
|
Joanne Bryce Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+39.94%
|
$22,500
$9.86 P/Share
|
|
Sep 01
2023
|
Joanne Bryce Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-44.25%
|
$52,000
$52.99 P/Share
|
|
Sep 01
2023
|
Joanne Bryce Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+30.67%
|
$2,000
$2.65 P/Share
|
|
Aug 21
2023
|
William Jacob Savage Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
$6,000
$2.65 P/Share
|
|
Aug 15
2023
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
72,931
-7.64%
|
$3,792,412
$52.4 P/Share
|
|
Aug 15
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
72,931
-7.64%
|
$3,792,412
$52.4 P/Share
|
|
Aug 15
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
111,069
-5.39%
|
$5,775,588
$52.4 P/Share
|
|
Aug 15
2023
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,672
-67.31%
|
$406,616
$53.16 P/Share
|
|
Aug 14
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
175,000
-2.66%
|
$9,275,000
$53.27 P/Share
|
|
Aug 09
2023
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,269
-21.47%
|
$413,450
$50.01 P/Share
|
|
Aug 01
2023
|
Joanne Bryce Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,521
-53.31%
|
$226,050
$50.07 P/Share
|
|
Aug 01
2023
|
Joanne Bryce Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,521
+43.88%
|
$4,521
$1.01 P/Share
|
|
Jun 30
2023
|
Brian Richard Mac Donald Chief Innovation Officer |
BUY
Open market or private sale
|
Direct |
600
+4.66%
|
$27,600
$46.76 P/Share
|
|
Jun 30
2023
|
Brian Richard Mac Donald Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
4,324
-13.4%
|
$194,580
$45.15 P/Share
|
|
Jun 29
2023
|
Brian Richard Mac Donald Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
5,100
-6.2%
|
$229,500
$45.9 P/Share
|
|
Jun 28
2023
|
Brian Richard Mac Donald Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
5,100
-6.62%
|
$255,000
$50.14 P/Share
|
|
Jun 28
2023
|
Joanne Bryce Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,072
-46.6%
|
$503,600
$50.34 P/Share
|
|
Jun 28
2023
|
Joanne Bryce Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,880
+41.02%
|
$7,880
$1.01 P/Share
|
|
Jun 28
2023
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,384
-7.78%
|
$214,816
$49.97 P/Share
|
|
Jun 28
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,250,000
-53.4%
|
$57,500,000
$46.1 P/Share
|
|
Feb 15
2023
|
Mona Ashiya Director |
BUY
Open market or private purchase
|
Indirect |
108,696
+4.57%
|
$2,500,008
$23.0 P/Share
|
|
Feb 15
2023
|
Ai Dmi LLC |
BUY
Open market or private purchase
|
Direct |
434,783
+12.16%
|
$10,000,009
$23.0 P/Share
|
|
Feb 15
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
108,696
+4.57%
|
$2,500,008
$23.0 P/Share
|
|
Dec 29
2022
|
Orbimed Advisors LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
2,160,941
+41.82%
|
-
|
|
Dec 29
2022
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
882,224
+48.02%
|
-
|
|
Dec 29
2022
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
1,835,799
+45.07%
|
-
|
|
Oct 26
2022
|
Braden Michael Leonard > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
22,500
-8.33%
|
$45,000
$2.09 P/Share
|
|
May 31
2022
|
Brian Piekos CFO |
BUY
Grant, award, or other acquisition
|
Direct |
9,960
+36.12%
|
$9,960
$1.09 P/Share
|
|
Apr 13
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
191,769
+3.69%
|
$191,769
$1.52 P/Share
|
|
Apr 12
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
203,744
+4.07%
|
$203,744
$1.42 P/Share
|
|
Apr 12
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
55,000
+16.92%
|
$55,000
$1.36 P/Share
|
|
Apr 11
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
504,487
+9.87%
|
$504,487
$1.35 P/Share
|
|
May 14
2021
|
Brian Piekos CFO |
BUY
Open market or private purchase
|
Direct |
7,655
+50.0%
|
$68,895
$9.46 P/Share
|
|
May 14
2021
|
Jason Patrick Meyenburg Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
13,000
+50.0%
|
$117,000
$9.46 P/Share
|
|
Feb 05
2021
|
James B. Tananbaum Director |
BUY
Conversion of derivative security
|
Indirect |
2,928,750
+50.0%
|
-
|
|
Feb 05
2021
|
James B. Tananbaum Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,500,000
+50.0%
|
$15,000,000
$10.0 P/Share
|
|
Feb 05
2021
|
Fs Development Holdings, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,928,750
+50.0%
|
-
|
|
Feb 05
2021
|
Fs Development Holdings, LLC > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
1,500,000
+50.0%
|
$15,000,000
$10.0 P/Share
|
|
Aug 14
2020
|
Fs Development Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
441,500
+50.0%
|
$4,415,000
$10.0 P/Share
|